Overview

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

Status:
Recruiting

Trial end date:
2024-06-30

Target enrollment:
0

Participant gender:
All

Summary

Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However, many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc seriously affects the prognosis of patients. Argatroban is kind of direct thrombin inhibitors, which could be used used as an alternative anticoagulant of unfractionated heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with unfractionated heparin.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Beijing Chao Yang Hospital

Treatments:

Argatroban
Calcium heparin
Heparin

Criteria

Inclusion Criteria:

- age older than 18 years old; received V-V ECMO because of sevever respiratory failure

Exclusion Criteria:

- anticoagulant contraindications; Confirmed or suspected, or previously diagnosed with
heparin induced thrombocytopenia; Cerebral infarction or suspected patients; Patients
with severe liver dysfunction; Allergic to heparin or argatroban; hemophilia;
Unwilling or unable to complete the study.